---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-000889"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:47:01.078457+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics reports FY2024 results: net loss $16.5M, cash $1.2M, and progress on SIL204

## Summary
- Net loss for 2024 was $16.5 million, compared to $5.1 million in 2023.
- Cash and cash equivalents as of December 31, 2024 were $1.2 million, down from $4.6 million.
- SIL204 showed significant reduction in primary tumor and metastasis in orthotopic pancreatic cancer models.
- Company raised approximately $9.1 million in gross proceeds from financings in early 2025.
- LODER Phase 2 trial achieved 56% objective response rate in patients with KRAS G12D/V mutations.

## SEC filing metadata
- accession: 0001178913-25-000889
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/0001178913-25-000889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/zk2532884.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-000889
- JSON: https://secwatch.observer/filing/0001178913-25-000889.json
- Plain text: https://secwatch.observer/filing/0001178913-25-000889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.